Wednesday May 23, 7:31 am Eastern Time
Press Release
Robert Taber, Former Dupont Vice President, Joins
Palatin Board
PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2001--Palatin Technologies, Inc.
(AMEX: PTN - news) today announced the appointment of Robert Taber, Ph.D., to the
company's board of directors.
Dr. Taber is the former vice president of pharmaceutical research of DuPont
Pharmaceuticals, and most recently served as co-founder and chief executive officer of
Message Pharmaceuticals, Inc., a private start-up biotechnology company developing a drug
discovery platform based on RNA regulation.
``We are very pleased to welcome Dr. Taber to the Palatin Board,'' said John Prendergast,
Ph.D., chairman of Palatin. ``He brings considerable expertise in drug discovery and
development, as well as both large and small company perspectives regarding the
establishment of productive corporate collaborations. His input will be of tremendous value
as we advance our products through preclinical and clinical development, and seek to
leverage the value of our MIDAS discovery platform, both for our own product pipeline and
for that of potential partners.''
Dr. Taber began his long career in the pharmaceutical industry in 1962, holding a succession
of positions within Schering Corporation's biological research group ending in 1982 as
director of biological research. During subsequent years, he held a number of positions with
increasing responsibilities at DuPont Pharmaceuticals and the DuPont Merck Pharmaceutical
Company including director of pharmaceutical research, director of pharmaceutical and
biotechnology research, vice president of pharmaceutical research and vice president of
extramural research and development. From 1994 to 1998 Dr. Taber held the position of
senior vice president of research and development at Synaptic Pharmaceuticals Corporation
before founding Message Pharmaceuticals, Inc. in 1998.
Dr. Taber holds a Ph.D. in pharmacology from the Medical College of Virginia. He received
the Distinguished Graduate Award from the Medical College of Virginia and was the first
recipient of the DuPont Merck Research and Development Award of Excellence. He is the
author of over 50 papers and abstracts.
Palatin Technologies, Inc. is a development-stage biopharmaceutical technology company
developing and commercializing pharmaceutical products for diagnostic imaging and therapy
based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. For further information
visit the Palatin web site at www.palatin.com.
Statements about the Company's future expectations, including development and regulatory plans, and all other statements in
this document other than historical facts, are ``forward-looking statements'' within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation
Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created
thereby.
Palatin's actual results may differ materially from its historical results of operations and those discussed in the forward-looking
statements for various reasons, including, but not limited to the Company's ability to carry out its business plan, successful
development and commercial acceptance of its products, ability to fund development of technology, the risk that products may
not result from development activities, protection of its intellectual property, ability to establish and successfully complete clinical
trials for product approval, need for regulatory approvals, dependence on it partners for development of certain projects, and
other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not
responsible for events not updated after the date on this press release.
Contact:
Palatin Technologies, Inc.
Carl Spana, Ph.D.
cspana@palatin.com
Stephen T. Wills, CPA, MST
swills@palatin.com
609/520-1911
or
Kureczka/Martin Associates (Media)
Joan Kureczka/Jesse Fisher, 415/821-2413
Jkureczka@aol.com |
